The National Institute for Health and Clinical Excellence has released draft guidelines to recommend against NHS provision of Roche's Avastin (generic name bevacizumab) for advanced breast cancer, stating that clinical trials of the drug produced "uncertain evidence".

Full article

Update: US panel rejects Roche's Avastin for breast cancer (Reuters, 20 July 2010).